Skip to main content

Role of LRRK2 kinase dysfunction in Parkinson disease

  • Azad Kumar (a1) and Mark R. Cookson (a1)

Parkinson disease is a common and usually sporadic neurodegenerative disorder. However, a subset of cases are inherited and, of these, mutations in the gene encoding leucine-rich repeat kinase 2 (LRRK2) are the most frequent genetic cause of disease. Here, we will discuss recent progress in understanding how LRRK2 mutations lead to disease and how this might have therapeutic implications. The effect of mutations on LRRK2 enzyme function provides clues as to which functions of the protein are important to disease. Recent work has focused on the kinase and GTP-binding domains of LRRK2, and it is assumed that these will be therapeutically important, although there is a substantial amount of work to be done to address this hypothesis.

Corresponding author
*Corresponding author: Mark R. Cookson, Cell Biology and Gene Expression Unit, Laboratory of Neurogenetics, National Institute on Aging, 35 Convent Drive, Bethesda, MD 20892-3707, USA. E-mail:
Hide All
1Cookson M.R. (2005) The biochemistry of Parkinson's disease. Annual Reviews of Biochemistry 74, 29-52
2Cookson M.R. and Bandmann O. (2010) Parkinson's disease: insights from pathways. Human Molecular Genetics 19, R21-R27
3Hardy J. (2010) Genetic analysis of pathways to Parkinson disease. Neuron 68, 201-206
4Cookson M.R. (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nature Reviews. Neuroscience 11, 791-797
5Taymans J.M. and Cookson M.R. (2010) Mechanisms in dominant parkinsonism: the toxic triangle of LRRK2, alpha-synuclein, and tau. Bioessays 32, 227-235
6Manning G. et al. (2002) The protein kinase complement of the human genome. Science 298, 1912-1934
7Marin I., van Egmond W.N. and van Haastert P.J. (2008) The Roco protein family: a functional perspective. FASEB Journal 22, 3103-3110
8Gotthardt K. et al. (2008) Structure of the Roc-COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase. EMBO Journal 27, 2239-2249
9Berger Z., Smith K.A. and Lavoie M.J. (2010) Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation. Biochemistry 49, 5511-5523
10Dzamko N. et al. (2010) Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14–3–3 binding and altered cytoplasmic localization. Biochemical Journal 430, 405-413
11Giasson B.I. et al. (2006) Biochemical and pathological characterization of Lrrk2. Annals of Neurology 59, 315-322
12Greggio E. et al. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiology of Disease 23, 329-341
13Nichols R.J. et al. (2010) 14–3–3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochemical Journal 430, 393-404
14West A.B. et al. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proceedings of the National Academy of Sciences of the United States of America 102, 16842-16847
15Deng J. et al. (2008) Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proceedings of the National Academy of Sciences of the United States of America 105, 1499-1504
16Guo L. et al. (2007) The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Experimental Cell Research 313, 3658-3670
17Lewis P.A. et al. (2007) The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochemical and Biophysical Research Communications 357, 668-671
18Li X. et al. (2007) Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. Journal of Neurochemistry 103, 238-247
19Ito G. et al. (2007) GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry 46, 1380-1388
20Liu M. et al. (2010) Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities. Biochemistry 49, 2008-2017
21Gloeckner C.J. et al. (2010) Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2. Journal of Proteome Research 9, 1738-1745
22Greggio E. et al. (2009) The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites. Biochemical and Biophysical Research Communications 389, 449-454
23Kamikawaji S., Ito G. and Iwatsubo T. (2009) Identification of the autophosphorylation sites of LRRK2. Biochemistry 48, 10963-10975
24Pungaliya P.P. et al. (2010) Identification and characterization of a leucine-rich repeat kinase 2 (LRRK2) consensus phosphorylation motif. PLoS One 5, e13672
25Greggio E. et al. (2008) The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. Journal of Biological Chemistry 283, 16906-16914
26Jorgensen N.D. et al. (2009) The WD40 domain is required for LRRK2 neurotoxicity. PLoS One 4, e8463
27Klein C.L. et al. (2009) Homo- and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment. Journal of Neurochemistry 111, 703-715
28Ko H.S. et al. (2009) CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proceedings of the National Academy of Sciences of the United States of America 106, 2897-2902
29Lu B. et al. (2010) Expression, purification and preliminary biochemical studies of the N-terminal domain of leucine-rich repeat kinase 2. Biochimica et Biophysica Acta 1804, 1780-1784
30Sen S., Webber P.J. and West A.B. (2009) Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization. Journal of Biological Chemistry 284, 36346-36356
31Alegre-Abarrategui J. et al. (2009) LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Human Molecular Genetics 18, 4022-4034
32Hatano T. et al. (2007) Leucine-rich repeat kinase 2 associates with lipid rafts. Human Molecular Genetics 16, 678-690
33Miklossy J. et al. (2006) LRRK2 expression in normal and pathologic human brain and in human cell lines. Journal of Neuropathology and Experimental Neurology 65, 953-963
34Biskup S. et al. (2006) Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Annals of Neurology 60, 557-569
35Higashi S. et al. (2009) Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease. Journal of Neuropathology and Experimental Neurology 68, 994-1005
36Funayama M. et al. (2002) A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2–q13.1. Annals of Neurology 51, 296-301
37Paisan-Ruiz C. et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600
38Zimprich A. et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607
39Funayama M. et al. (2005) An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Annals of Neurology 57, 918-921
40Gilks W.P. et al. (2005) A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365, 415-416
41Goldwurm S. et al. (2005) The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. Journal of Medical Genetics 42, e65
42Infante J. et al. (2006) LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson's disease. Neuroscience Letters 395, 224-226
43Kachergus J. et al. (2005) Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. American Journal of Human Genetics 76, 672-680
44Lesage S. et al. (2006) LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. New England Journal of Medicine 354, 422-423
45Lesage S. et al. (2005) G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Annals of Neurology 58, 784-787
46Lesage S. et al. (2005) LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. American Journal of Human Genetics 77, 330-332
47Ozelius L.J. et al. (2006) LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. New England Journal of Medicine 354, 424-425
48Rajput A. et al. (2006) Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 67, 1506-1508
49Kumari U. and Tan E.K. (2009) LRRK2 in Parkinson's disease: genetic and clinical studies from patients. FEBS Journal 276, 6455-6463
50Greggio E. and Cookson M.R. (2009) Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro 1, e0002
51Daniels V. et al. (2011) Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. Journal of Neurochemistry 116, 304-315
52West A.B. et al. (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Human Molecular Genetics 16, 223-232
53Haugarvoll K. and Wszolek Z.K. (2009) Clinical features of LRRK2 parkinsonism. Parkinsonism and Related Disorders 15 (Suppl 3), S205-S208
54Alcalay R.N. et al. (2010) Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. Archives of Neurology 67, 1116-1122
55Goldstein D.S. et al. (2007) Neurocirculatory and nigrostriatal abnormalities in Parkinson disease from LRRK2 mutation. Neurology 69, 1580-1584
56Wider C., Dickson D.W. and Wszolek Z.K. (2010) Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation. Neurodegenerative Diseases 7, 175-179
57Cookson M.R., Hardy J. and Lewis P.A. (2008) Genetic neuropathology of Parkinson's disease. International Journal Clinical Experimental Pathology 1, 217-231
58Kay D.M. et al. (2005) Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation. Movement Disorders 20, 1077-1078
59Dachsel J.C. and Farrer M.J. (2010) LRRK2 and Parkinson disease. Archives of Neurology 67, 542-547
60Clark L.N. et al. (2006) Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology 67, 1786-1791
61Ruiz-Martinez J. et al. (2010) Penetrance in Parkinson's disease related to the LRRK2 R1441G mutation in the Basque country (Spain). Movement Disorders 25, 2340-2345
62Gehrke S. et al. (2010) Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 466, 637-641
63Imai Y. et al. (2008) Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO Journal 27, 2432-2443
64Kanao T. et al. (2010) Activation of FoxO by LRRK2 induces expression of proapoptotic proteins and alters survival of postmitotic dopaminergic neuron in Drosophila. Human Molecular Genetics 19, 3747-3758
65Lee S. et al. (2010) LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the Drosophila neuromuscular junction. Journal of Neuroscience 30, 16959-16969
66Lee S.B. et al. (2007) Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in Drosophila. Biochemical and Biophysical Research Communications 358, 534-539
67Lin C.H. et al. (2010) LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3ss. Journal of Neuroscience 30, 13138-13149
68Liu Z. et al. (2008) A Drosophila model for LRRK2-linked parkinsonism. Proceedings of the National Academy of Sciences of the United States of America 105, 2693-2698
69Ng C.H. et al. (2009) Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. Journal of Neuroscience 29, 11257-11262
70Tain L.S. et al. (2009) Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nature Neuroscience 12, 1129-1135
71Venderova K. et al. (2009) Leucine-rich repeat kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease. Human Molecular Genetics 18, 4390-4404
72Hsu C.H. et al. (2010) MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2. Journal of Neurochemistry 112, 1593-1604
73Saha S. et al. (2009) LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. Journal of Neuroscience 29, 9210-9218
74Sakaguchi-Nakashima A. et al. (2007) LRK-1, a C. elegans PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins. Current Biology 17, 592-598
75Samann J. et al. (2009) Caenorhabditits elegans LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth. Journal of Biological Chemistry 284, 16482-16491
76Yao C. et al. (2010) LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease. Neurobiology of Disease 40, 73-81
77Wang D. et al. (2008) Dispensable role of Drosophila ortholog of LRRK2 kinase activity in survival of dopaminergic neurons. Molecular Neurodegeneration 3, 3
78Marin I. (2008) Ancient origin of the Parkinson disease gene LRRK2. Journal of Molecular Evolution 67, 41-50
79Andres-Mateos E. et al. (2009) Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). Journal of Neuroscience 29, 15846-15850
80Lin X. et al. (2009) Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 64, 807-827
81Tong Y. et al. (2010) Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proceedings of the National Academy of Sciences of the United States of America 107, 9879-9884
82Tong Y. et al. (2009) R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proceedings of the National Academy of Sciences of the United States of America 106, 14622-14627
83Li X. et al. (2010) Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. Journal of Neuroscience 30, 1788-1797
84Li Y. et al. (2009) Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nature Neuroscience 12, 826-828
85Melrose H.L. et al. (2010) Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiology of Disease 40, 503-517
86Winner B. et al. (2011) Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice. Neurobiology of Disease 41, 706-716
87Lee B.D. et al. (2010) Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nature Medicine 16, 998-1000
88Dusonchet J. et al. (2011) A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2. Journal of Neuroscience 31, 907-912
89Dachsel J.C. et al. (2010) A comparative study of Lrrk2 function in primary neuronal cultures. Parkinsonism and Related Disorders 16, 650-655
90MacLeod D. et al. (2006) The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52, 587-593
91Parisiadou L. et al. (2009) Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. Journal of Neuroscience 29, 13971-13980
92Nuytemans K. et al. (2010) Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Human Mutation 31, 763-780
93Satake W. et al. (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nature Genetics 41, 1303-1307
94Simon-Sanchez J. et al. (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nature Genetics 41, 1308-1312
95Smith W.W. et al. (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nature Neuroscience 9, 1231-1233
96Liu M. et al. (2010) Development of a mechanism-based high-throughput screen assay for leucine-rich repeat kinase 2 – discovery of LRRK2 inhibitors. Analytical Biochemistry 404, 186-192
97Nichols R.J. et al. (2009) Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochemical Journal 424, 47-60
98Reichling L.J. and Riddle S.M. (2009) Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity. Biochemical and Biophysical Research Communications 384, 255-258
99Deng X. et al. (2011) Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nature Chemical Biology 7, 203–25
Cookson M.R. (2010). The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nature Reviews Neuroscience 11, 791-797
Greggio E. and Cookson M.R. (2009) Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro 1, e0002
General information about PD research can be found at PDOnline:
Up-to-date information on inherited forms of PD can be obtained from the OMIM (online inheritance in man) website:
Additional data on the association of specific genetic variants with PD can be found at pdgene:
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *


Altmetric attention score

Full text views

Total number of HTML views: 7
Total number of PDF views: 23 *
Loading metrics...

Abstract views

Total abstract views: 248 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 21st January 2018. This data will be updated every 24 hours.